Aligos Therapeutics (ALGS) Leases (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Leases for 5 consecutive years, with $3.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 37.77% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, down 37.77%, and an annual FY2025 reading of $3.1 million, down 37.77% over the prior year.
- Leases was $3.1 million for Q4 2025 at Aligos Therapeutics, down from $3.6 million in the prior quarter.
- Across five years, Leases topped out at $8.8 million in Q4 2021 and bottomed at $3.1 million in Q4 2025.
- Average Leases over 5 years is $6.4 million, with a median of $6.8 million recorded in 2021.
- The sharpest move saw Leases increased 25.99% in 2022, then tumbled 37.77% in 2025.
- Year by year, Leases stood at $8.8 million in 2021, then fell by 12.41% to $7.7 million in 2022, then decreased by 14.8% to $6.6 million in 2023, then decreased by 24.32% to $5.0 million in 2024, then tumbled by 37.77% to $3.1 million in 2025.
- Business Quant data shows Leases for ALGS at $3.1 million in Q4 2025, $3.6 million in Q3 2025, and $4.1 million in Q2 2025.